Inflammation is a common albeit overlooked cause of local and systemic bone loss which results from an imbalance between bone formation and bone resorption. The Wnt pathway, which plays an essential role in the regulation of bone turnover, has been proposed as a potential molecular link between inflammation and inflammatory bone loss. We here recapitulate present knowledge about sclerostin, a Wnt pathway inhibitor, and bone damage in inflammation. A better understanding of sclerostin action and regulation might help in designing an effective treatment strategy in inflammatory bone loss.
MoesterMJCPapapoulosSELöwikCWGMvan BezooijenRL. Sclerostin: Current knowledge and future perspectives. Calcif Tissue Int2010; 87:99–107.
2.
LiCOminskyMSTanHL. Increased callus mass and enhanced strength during fracture healing in mice lacking the sclerostin gene. Bone2011; 49(6): 1178–85.
3.
BalemansWEbelingMPatelN. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet2001; 10:537–43.
4.
RoblingAGNiziolekPJBaldridgeLA. Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. J Biol Chem2008; 283(9):5866–75.
5.
CleversH. Wnt/beta-catenin signaling in development and disease. Cell2006; 127:469–80.
6.
BaronRRawadiG. Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology2007; 148(6):2635–43.
7.
LiXZhangYKangHLiuWLiuPZhangJHarrisSEWuD. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem2005; 280:19883–87.
8.
LeupinOHalleuxCMorvanFHuSLuCBauerAKneisselM. LRP4 is a novel osteoblast and osteocyte expressed specific facilitator of SOST-mediated inhibition of in vitro bone formation. J Bon Miner Res2009; 24:S1.
9.
PooleKEvan BezooijenRLLoveridgeNHamersmaHPapapoulosSELöwikCWGMReeveJ. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J2005; 19:1842–1844.
10.
Baker-LePainJCNakamuraMCLaneNE. Effects of inflammation on bone: An update. Curr Opin Rheumatol2011; 23(4):389–95.
11.
GeorgeSJ. Wnt pathway: A new role in regulation of inflammation. Arterioscler Thromb Vasc Biol2008; 28(3):400–2.
12.
RedlichKGörtzBHayerS. Repair of local bone erosions and reversal of systemic bone loss upon therapy with anti-tumor necrosis factor in combination with osteoprotegerin or parathyroid hormone in tumor necrosis factor-mediated arthritis. Am J Pathol2004; 164(2):543–55.
13.
LinCLMonizCChambersTJChowJW. Colitis causes bone loss in rats through suppression of bone formation. Gastroenterology1996; 111:1263–71.
Graat-VerboomLSmeenkFWvan den BorneBESpruitMARossumAB Donkers-VanAartsRPWoutersEF. Risk factors for osteoporosis in Caucasian patients with moderate chronic obstructive pulmonary disease: A case control study. Bone2012; 50(6): 1234–9.
16.
YoshiharaASeidaYHanadaNMiyazakiH. A longitudinal study of the relationship between periodontal disease and bone mineral density in community-dwelling older adults. J Clin Periodontol2004; 31(8):680–4.
17.
AtkinsGJKostakisPPanBFarrugiaAGronthosSEvdokiouAHarrisonKFindlayDMZannettinoAC. RANKL expression is related to the differentiation state of human osteoblasts. J Bone Miner Res2003; 18(6):1088–98.
18.
VincentCFindlayDMWelldonKJ. Proinflammatory cytokines TNF-related weak inducer of apoptosis (TWEAK) and TNF-α induce the mitogen-activated protein kinase (MAPK)-dependent expression of sclerostin in human osteoblasts. J Bone Miner Res2009; 24:1434–49.
19.
ChicheporticheYChicheporticheRSizingIThompsonJBenjaminCBAmbroseCDayerJM. Proinflammatory activity of TWEAK on human dermal fibroblasts and synoviocytes: Blocking and enhancing effects of anti-TWEAK monoclonal antibodies. Arthritis Res2002; 4(2): 126–33.
20.
WeinsteinRSJilkaRLParfittAMManolagasSC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest1998; 102(2):274–82.
21.
HofbauerLCGoriFRiggsBLLaceyDLDunstanCRSpeisbergTCKhoslaS. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: Potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology. 1999; 140(10):4382–9.
22.
HayashiKYamaguchiTYanoS. BMP/Wnt antagonists are upregulated by dexamethasone in osteoblasts and reversed by alendronate and PTH: Potential therapeutic targets for glucocorticoid-induced osteoporosis. Biochem Biophys Res Commun2009; 379:261–66.
23.
YunSIYoonHYJeongSYChungYS. Glucocorticoid induces apoptosis of osteoblast cells through the activation of glycogen synthase kinase 3beta. J Bone Miner Metab2009; 27(2): 140–8.
24.
YaoWChengZPhamABusseCZimmermanEARitchieROLaneNE. Glucocorticoid-induced bone loss in mice can be reversed by the actions of parathyroid hormone and risedronate on different pathways for bone formation and mineralization. Arthritis Reum2008; 58:3485–97.
25.
MarenzanaMGreensladeKEddlestonAOkoyeRMarshallDMooreARobinsonMK. Sclerostin antibody treatment enhances bone strength but does not prevent growth retardation in young mice treated with dexamethasone. Arthritis Rheum2001; 63:2385–95.
26.
van LieropAHvan der EerdenAWHamdyNAHermusARden HeijerMPapapoulosSE. Circulating sclerostin levels are decreased in patients with endogenous hypercortisolism and increase after treatment. J Clin Endocrinol Metab2012; 97(10):E 1953–7.
27.
DeanDBWatsonJTJinWPetersCEndersJTChenAMoedBRZhangZ. Distinct functionalities of bone morphogenetic protein antagonists during fracture healing in mice. J Anat2010; 216(5):625–30.
28.
Caetano-LopesJLopesARodriguesA. Upregulation of inflammatory genes and downregulation of sclerostin gene expression are key elements in the early phase of fragility fracture healing. PLoS One2011; 6(2):e16947.
29.
SarahrudiKThomasAAlbrechtCAharinejadS. Strongly enhanced levels of sclerostin during human fracture healing. J Orthop Res2012; 30(10): 1549–55.
30.
OminskyMSLiCLiX. Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones. J Bone Miner Res2011; 26(5): 1012–21.
31.
WehmeyerCStratisAPapT. The role of the WNT inhibitor sclerostin in rheumatoid arthritis. Ann Rheum Dis2010; 69:A1–A76.
32.
AppelHRuiz-HeilandGListingJ. Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthritis Rheum2009; 60:3257–62.
33.
FelsonDT. Developments in the clinical understanding of osteoarthritis. Arthritis Res Ther2009; 11:203.
34.
ChanBYFullerESRussellAK. Increased chondrocyte sclerostin may protect against cartilage degradation in osteoarthritis. Osteoarthritis Cartilage2011; 19(7):874–85.
35.
EddlestonAMarenzanaMMooreARStephensPMuzylakMMarshallDRobinsonMK. A short treatment with an antibody to sclerostin can inhibit bone loss in an ongoing model of colitis. J Bone Miner Res2009; 24:1662–71.
36.
GennariLMerlottiDValentiR. Circulating sclerostin levels and bone turnover in type 1 and type 2 diabetes. J Clin Endocrinol Metab2012; 97(5): 1737–44.
37.
Brooks-WorrellBPalmerJP. Immunology in the Clinic Review Series; focus on metabolic diseases: Development of islet autoimmune disease in type 2 diabetes patients: Potential sequelae of chronic inflammation. Clin Exp Immunol2012; 167(1):40–46.
38.
WijenayakaARKogawaMLimHPBonewaldLFFindlayDMAtkinsGJ. Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. PLoS One2011; 6(10):e25900.
39.
PadhiDJangGStouchBFangLPosvarE. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res2011; 26(1): 19–26.
